TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta ...

On Wednesday, H.C. Wainwright initiated coverage on NASDAQ-listed TuHURA Biosciences (NASDAQ: HURA), assigning a Buy rating and a price target of $11.00. Currently ...

Pre-market: 8:00:39 am GMT-5 ...

After hours: 7:51:12 p.m. EST Loading Chart for HURA ...

Market data, analyses and news for your industry.